Company: Rubicon Organics

Ticker: ROMJ.V

Operator: Good morning, everyone. Welcome to Rubicon Organics Q3 2026 earnings call for the three and nine months ended 30 September 2026. As a reminder, this call is being recorded. At this time, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions will be provided at that time for analysts to queue up for questions. Before we begin, please refer to slide two for our caution regarding forward-looking statements and non-GAAP measures. Today's presenters are Margaret Brodie, CEO, and Glen Ibbott, CFO. I will now turn the call over to Margaret.

Margaret Brodie: Good morning, everyone, and thank you for joining. Today, we will review our third quarter results and give you an update on the business. Q3 was another quarter of growth for Rubicon as we maintained our position as the number one premium licensed producer in Canada. Revenue was up 17% for both the three and nine-month periods compared with last year. International sales were 11.7% of net revenue in the quarter, marking the start of a meaningful contribution that we expect to keep growing in Q4 and into 2027. We also introduced our expedited path to scale to 20,000 kg, one year faster than originally planned, putting us in a stronger position to serve the growing demand for our brands and products more cost-efficiently. At Pacifica, production was up approximately 16% year-over-year through the first nine months of 2026.

Margaret Brodie: While Cascadia still has further to go to reach our production expectations, Q3 was its first full quarter of revenue contribution, and recent results give us high confidence we are on track. Later in the call, I will walk you through our yield improvement initiatives at Pacifica and progress at Cascadia, our manufacturing efficiency projects, our international progress, and our genetics program. Before then, some quick highlights to call out for Q3 include our total premium market share of 6.6%, up from 6.3% in the comparative period, including 9% of the premium flower market. We continue to see premium consumers trend toward larger flower formats, and increasing yield is key for us to service that demand more profitably. Market share gains in other fast-growing convenience formats, with 5.2% of premium pre-rolls and 6.5% of premium vapes.

Margaret Brodie: There are significant savings to be realized in the production of these categories, and I will touch upon these shortly. The launch of our Caviar-Z strain, which marks an important milestone for Rubicon as our first internally bred genetic to reach market. We see a broader opportunity to make proprietary genetics an increasingly important part of our strategy. Subsequent to quarter end, we completed a CAD 3 million private placement to fund lighting upgrades at Pacifica, putting Rubicon on track to 20,000 kg of premium capacity by mid-2027, a year earlier than originally expected. I will share more on that project and other key initiatives expected to increase our total volume and gross margins in a moment. For now, I will turn it over to Glen.

Glen Ibbott: Thank you, Margaret. Good morning, everyone. Net revenue for Q3 2026 was CAD 18.3 million, up 17% year-over-year. Year-to-date, net revenue was CAD 50.4 million, also up 17% from the comparative period. Our year-to-date growth has been primarily volume-driven. 1964 Supply Co grew approximately 20%, led by higher volumes across pre-rolls, dried flower, and vapes, while Simply Bare grew 9%, led by strong pre-roll performance and small gains in dried flower. International sales also increased meaningfully and represented an increasing share of our revenue. Cascadia contributed approximately CAD 2.3 million, or 12.3% of sales in its first full quarter of commercial contribution. This represents only the beginning of Cascadia's growth story, and we expect the facility to become a more significant contributor as production scales.

Glen Ibbott: Sequentially, revenue was essentially flat as we worked through our supply ramp-up, although as Margaret noted, we shifted the mix allocation a bit more towards international sales.

Glen Ibbott: Gross profit before fair value adjustments was CAD 5 million, compared with CAD 5.3 million Q3 of last year. Gross margin before fair value adjustments was 27%, compared with 34% in the prior year quarter and 30% in Q2 of 2026. The margin result reflects the transitional cost of operating Cascadia below targeted production levels, together with changes in our sales mix. Cascadia carries a largely fixed cultivation cost base, and as production scales, we expect these costs to be spread across more saleable product. International sales also represented a greater share of revenue in Q3. International sales have an attractive margin profile, but they do have a lower average selling price per unit, along with the lower post-harvest costs. However, the shift in mix does not change the largely fixed nature of our cost base.

Glen Ibbott: We expect margins to recover in 2027 as we realize the benefits of our margin improvement projects and refine our portfolio towards more profitable formats. Improving yield at Cascadia and increased production from the Pacifica lighting project will spread our largely fixed cultivation costs across more saleable product, while in-house hydrocarbon extraction is anticipated to lower vape manufacturing costs beginning in mid-2027. Operating expenses were CAD 5 million in Q3, down from CAD 6.9 million in Q2, and broadly consistent with Q3 of last year. The sequential decrease was largely due to adjustments to certain previously recorded accruals, partially offset by our continued investment in the people, brands, and infrastructure required to support our growth. Adjusted EBITDA was CAD 1.4 million, up from CAD 1.1 million in Q2, and down from CAD 1.7 million in Q3 of last year.

Glen Ibbott: When comparing across periods, it's worth noting that this quarter's Adjusted EBITDA doesn't exclude any pre-revenue Cascadia costs. The facility is now generating revenue, but at a lower level than we'd like and expect going forward, while we continue to carry its largely fixed costs. With regard to liquidity, we ended the quarter with CAD 4.2 million in cash and CAD 19.9 million in net working capital. Cash provided by operating activities was CAD 3.8 million in Q3, compared with CAD 0.5 million in Q3 of last year, reflecting both cash generated by operations and the timing of working capital collections and payments. Additionally, we have spent approximately CAD 4.5 million in CapEx projects year-to-date, focusing on increasing yield and improving manufacturing efficiency as we build towards 20,000 kg of annualized production with greater scale driving improved cost efficiency.

Glen Ibbott: With that, I'll turn the call back to Margaret.

Margaret Brodie: Thanks, Glen. One of the key initiatives we have undertaken to achieve that higher production target is the Pacifica lighting project. This project involves upgrading cultivation lighting and greenhouse infrastructure at Pacifica to increase crop yields. Lighting is one of the most important yield drivers for cannabis, and we anticipate this project to increase Pacifica's capacity by 40% annually. Most of the benefit from the lights will be realized during the winter months when natural light is lower, although we expect benefits all year round. The CAD 3 million strategic private placement we closed in October advanced the project timeline by approximately one year. The economics of the project were very compelling, so we chose to raise the funds from equity instead of waiting to fund from cash flows. Three cultivation compartments have now been upgraded, and the project is expected to be substantially complete by mid-December.

Margaret Brodie: The full annualized capacity benefit is anticipated by June of 2027. Combined with the continued production ramp at Cascadia, the Pacifica upgrades are expected to bring Rubicon's annual rated capacity to approximately 20,000 kilos, roughly double where it stood two years ago. Now to other operational updates. As noted in our last quarterly earnings call, while Cascadia has taken longer to ramp up than we anticipate, we remain confident in this facility's potential to produce to our expectations. We are happy with the product quality from the facility, which meets our premium high standards, and was a significant factor supporting increased pre-roll production in Q3. However, the yield has been behind our expectations, which limits our ability to optimize our overall sales mix.

Margaret Brodie: One of the primary strategies in place to bring Cascadia to its full potential is the installation of new lighting completed in August to replace some of the underperforming existing lighting at the facility. Initial harvests under the new lights are coming down now and have shown a marked improvement in overall yield. Now, just over a year since the facility was licensed, we are also benefiting from the more tailored genetic selection and refined cultivation practices developed from site-specific harvest data. There is a natural lead time before cultivation changes appear in the financial results. It takes a minimum of approximately three months for a change to move through the crop cycle, followed by processing, product listing, and eventual sale of that product. While these improvements are already taking hold operationally, we expect their impact on our financial performance to become increasingly evident throughout 2027.

Margaret Brodie: Across Pacifica and Cascadia, we expect combined annual run rate to reach approximately 20,000 kilos by June of 2027. As demand has continually outpaced available supply, we are confident we have built the route to sell this additional supply through our domestic portfolio, undersupplied products, and growing international channels. Internationally, we now have four supply contracts signed, with additional opportunities under development. International sales represented 11.7% of Q3 net revenue, up 2.2% from Q2. As patient populations expand and markets mature, our focus is not simply on supplying volume. We believe our premium quality, consistency, and established brands position us to compete at the higher end of these markets. Our launch of the 1964 full-spectrum vapes in the UK in September is an early example of the strategy extending beyond flower. Staying with vapes, we have also taken significant steps to improve the margin profile of this format.

Margaret Brodie: Our in-house hydrocarbon extraction capability is nearing completion, with commercial production targeted to begin in the first quarter of 2027. Bringing this process in-house is expected to materially reduce production costs for our vape and extract products, while giving Rubicon end-to-end control over the manufacturing process. We expect the gross margin benefits to begin flowing through our results in the second half of 2027, as the in-house production increasingly replaces third-party supply. Pre-roll automation is now running at full expanded capacity, and August also marks the first period in which all pre-roll production was automated, improving both product consistency and labor input costs. Pre-rolls are one of the fastest-growing formats in the Canadian cannabis market, and we are well-positioned to continue to participate in that growth. Finally, subsequent to the quarter end, we recently announced Arbora, our licensed genetics facility located in Squamish, BC.

Margaret Brodie: Arbora will act as a dedicated home for the preservation, propagation, and development of Rubicon's library of over 500 cannabis genetics. It will allow us to expand our breeding program, identify unique strains, and translate them into products that stand out in the competitive premium market. Because genetics also play an important role in crop performance, we expect Arbora to help us to develop genetics that deliver the yield characteristics we target in cultivation while creating distinct premium products that strengthen and differentiate our brand portfolio. Caviar-Z, that I mentioned earlier, is our first internally bred genetic to reach market, and it is an early example of what our genetic programs can achieve, combining the differentiated qualities we look for in a premium product with the high yields we target in cultivation.

Margaret Brodie: We expect 2027 to be the year in which our investments in cultivation capacity, automation, and manufacturing capabilities come together. With that, I'll return it back to Glen to discuss our financial outlook for 2027.

Glen Ibbott: Thanks, Margaret. Looking ahead, we expect the investments and groundwork we've put into place to scale our production towards 20,000 kg will translate into stronger financial performance in 2027. We expect 2027 to be a year of margin improvements, EBITDA growth, and stronger cash flows as the investments we've made over 2025 and 2026 start to come in through our results. That means more saleable production, lower cost per unit, and a stronger product mix. These benefits will build through the year rather than arrive all at once, and 2026 remains the bridge year as these initiatives take hold. Well, first, it starts with supply. Demand in Canada and internationally for our brands continues to exceed what we can produce, so every additional kilogram of quality product has a home.

Glen Ibbott: That is why increasing our annualized production capacity to approximately 20,000 kg by June 2027 is such an important part of our strategy. Second, that additional production should drive our per-unit costs down. A large part of both our cultivation and manufacturing cost base are fixed, so as yields improve and manufacturing volumes grow, those costs are spread across more saleable product. Third, our manufacturing investments are designed to improve margins on a more structural basis. Our expanded pre-roll automation is now running at full capacity, which improves throughput and lowers labor cost per unit. With commercial production from our in-house hydrocarbon extraction targeted to start in Q1 2027, we expect the benefit to flow into gross margins in H2, particularly in our vape and concentrate portfolios. Finally, we're confident the market can absorb this additional volume.

Glen Ibbott: Our premium market share continues to grow. We now have four international contracts signed and more opportunities in progress. International growth also gives us an incremental margin opportunity, which supports the case for increasing our production. We estimate international sales will make up around 15% of our revenue in 2027. Domestically, in Canada, we see the opportunity to service the existing unmet demand for our leading premium brand portfolio nationwide, including in larger flower formats, where we feel our growing scale and improving cost basis will allow an increased ability to compete in a profitable manner. Put simply, more saleable product, a lower cost per unit, and a better product and geography mix are how we expect revenue growth to convert into stronger margins, EBITDA, and cash flow in 2027. Our focus remains on execution, and we will keep updating you on our progress each quarter.

Glen Ibbott: With that, I'll turn the call back to Margaret.

Margaret Brodie: Before we open the line, I'd like to comment on why we believe now is the right time to be paying attention to Rubicon. Three things have shifted, and together they create a meaningful moment. First, the cannabis industry continues to evolve. Weak operators are exiting or pivoting, and shelf space is concentrating around brands that can demonstrate consistent quality, reliable supply, and real consumer loyalty. We're seeing this in Canada and internationally, and in that environment, Rubicon's position as a well-known leading premium producer with proven brands and consumer trust becomes increasingly valuable. Second, trading liquidity across the cannabis sector has increased meaningfully. Volumes are up sharply, and new investors are taking positions as US and international developments draw attention to the space. That creates a better backdrop for the markets to engage with our story.

Margaret Brodie: Third, and most importantly, as Glen outlined, the investment cycle that defined 2025 and 2026 is positioned to convert to results in 2027. Cascadia is now generating revenue and scaling towards full capacity. International is already contributing, and our manufacturing investments are only just beginning to show up in results. Our recent strategic financing has also allowed us to accelerate the Pacifica lighting projects, which together with Cascadia, puts us on track for a larger footprint of premium supply. That is the core of the why now story: established brand demand, more supply to service, better use of our existing assets, and several operational improvements expected to contribute to revenue margin and cash flow growth in 2027. With that, let's move to questions.

Operator: Ladies and gentlemen, we will now begin the question-and-answer session. If you would like to ask a question, please press star, then number one on your telephone keypad. If you would like to withdraw a question, please press star, then the number two. Again, that will be star, then the number one on your telephone keypad. We have our first question, comes from Neal Gilmer with Haywood Securities. Please go ahead.

Neal Gilmer: Yeah, good morning. Thanks for the questions. Glen, towards the end there, just sort of answered my question, but wondering if you can elaborate on it. He mentioned that in 2027, you expect 15% of revenues to be international. I was curious, as you scale to the 20,000 kilogram capacity mid-next year, what is your sort of strategy or philosophy as far as how you allocate that increased production to domestic versus international markets?

Margaret Brodie: Thanks, Neal, and good morning. We do expect next year to be north of 15% in our international revenue. What we have done is looked at where is the profitability. So in the Canadian market, this is sort of a balancing act between maximizing the gross margin potential within the SKUs here and allocating to international. With our international program, we have given that there is risk potentially in various markets as they ebb and flow, which we have seen over the last number of years. That is why our strategy has been to sign multiple agreements, but also take advantage of the spot market. Currently, we are in a real supply need for the international markets.

Margaret Brodie: The inbounds are very strong, and it is about having the product to be available to sell. So we are looking at more of a matrix structure to maximize that than putting all of our eggs in one basket.

Neal Gilmer: Okay. Thanks, Margaret. You have touched on a number of different things with respect to it. First off, Cascadia, you talked about the improving yields there that you have seen from the change you made in August. The pre-roll automation is in and obviously running. You have already done three rooms at Pacifica with the lighting. As we look at gross margins in the near term, I understand the full benefits is not until the H2 of next year, but should we think of Q3 as sort of the trough here and we start a gradual increase from here with some of the benefits of those actions already implemented?

Margaret Brodie: Good question. Majority of those benefits are going to be seen in 2027. Obviously frustrating that Q1 is a typical seasonal dip on revenue, which means on the fixed cost base, that is more challenging to deliver. Yes, we are very confident in what we are seeing out of Cascadia today in the recent crops that have come down over the course of the last month, that we are on the track for where we want to be. Pre-roll automation definitely having an impact. With three compartments already in, we should see first yields available for sale in March of next year by the time it is grown. The first compartment went in 6 October, it began. The lights when the plants went under a week later after the installation. There are a few months drying, curing, trimming, et cetera.

Margaret Brodie: By the time it is actually into the revenue, the first crop will likely be March of next year. Obviously, that is when the boards in Canada do their inventory counts and slow down their purchasing a bit. We are feeling very confident coming towards the Q2 of next year, we will really see that bounce back.

Neal Gilmer: Thanks. Maybe one last housekeeping one for me. Glen, you mentioned CAD 4.5 million in CapEx year-to-date. What is sort of left to complete hydrocarbon and the lights for Pacifica?

Glen Ibbott: Well, the Pacifica lighting project, in terms of cash out the door, there is a little bit left in December, but Neal, the payments schedule we have actually goes into next year. So, there is not that much left in 2026. As far as the hydrocarbon project goes, it is pretty much wrapped up in terms of a few hundred thousand dollars still for work on it. But in terms of the major CapEx, it is pretty much wrapped up. So Q4, mainly some lighting costs that flow into next year, and then not too much other than that. Those are the two major projects we focused on.

Margaret Brodie: At this stage, as we look towards 2027, we do not have any significant projects that we are looking at today. We will be reporting that as we go on in general maintenance, et cetera.

Neal Gilmer: Great. Thanks for your time, guys.

Margaret Brodie: Thank you.

Operator: Your next question comes from Pablo Zuanic from Zuanic & Associates. Please go ahead.

Pablo Zuanic: Thank you, and good morning, everyone. Margaret, can I start on the domestic side, looking at the Hifyre data, which you also shared? About two years ago, your flower sales were slightly higher than your pre-roll sales, and now I think in Q3, pre-rolls are like two times your flower sales. So first, do those numbers match with what you have? If you can talk about that change in mix, what does it do to margins internally? That's the first question. The second one, just more broader, bigger picture about the market. I see that in the case of pre-rolls, a lot of the innovation from various LPs in standard pre-rolls is around pack sizes. I wonder what's your flexibility there in terms of adjusting pack sizes in pre-rolls?

Pablo Zuanic: I know we've talked about opportunity in flower, but pre-rolls are a much larger percentage of your sales now. Thank you.

Margaret Brodie: Very good. I'm going to ask Glen to take the one on pre-roll versus flower, and I would say we definitely see that trend and the rise of convenience continuing.

Glen Ibbott: Pablo, I think you would have seen the last several quarters, our pre-roll business is really taking off, both in Simply Bare and 1964 Supply Co. In terms of what you're seeing in proportions, I think in Simply Bare, it's true that recently, probably twice as much or close to two times pre-rolls versus flower. 1964 Supply Co is a bit more balanced in terms of the mix. But as Margaret just mentioned, I think the trend is definitely towards the convenience factor. You asked how that impacts margins. Fortunately, I think we saw this. We saw this trend coming. We've invested in the pre-roll automation. As we continue to get the yields out of our facilities, the margin profile on most of the pre-roll formats is actually quite strong. This is where we need to actively manage the portfolio mix.

Glen Ibbott: There are certain pre-roll formats that aren't as strong on the margin side, and we tend to de-emphasize those and focus in on where the volumes and the margins make sense. Because fortunately, I think we have lots of allocation opportunities for our flower, so we can put it in the pre-roll, we can send it internationally, it can go into certain flower formats. So, we're always looking at that margin impact. But yeah, lots of uptick on the pre-rolls and good margin profile for Rubicon.

Pablo Zuanic: Okay. Thank you. Just to follow up, Margaret, obviously the international side, you give a little more disclosure than your peers, right? So, I guess I want to take advantage of that here. You talked about having four contracts. If you can remind us in which countries are those? That's the first part to the question. The second one, when you look at the international demand for premium, if you compare Germany and the UK, is there any nuance there that the demand for premium is greater in the UK versus Germany? We hear a lot about deflation in Germany. If you can talk about that. Thank you.

Margaret Brodie: The first question on the four contracts. We are selling to lots of countries through spot buys in addition to that. We are branded in the UK with 4C LABS. That's the only one that's disclosed. We have arrangements in Germany, some contracted, some spot, and then in Australia as well, those that we are selling to today. All of those are meaningful, and we're just beginning to see the ramp of that. The lead time on international is actually quite long in terms of making sure you've got export permits and getting things lined up. That is now underway. Your question on the demand for premium is interesting. I would say we're seeing the markets each evolve very similarly to what's happened in Canada. The beginning was a desire for a product at any price, which is highest THC, lowest cost.

Margaret Brodie: As, in particular, the companies are looking to differentiate themselves in the market, they're looking to build brand. And we are seeing certain houses and brands looking for that consistent premium supply to build those brands, and that's been a challenge. Many contract grows in Canada that do sell are either mainstream, or if they're in the premium segment, they're quite small lots that are available, i.e., you can buy 30 kilos or 40 kilos versus consistently being able to get month after month 100 kilos of a product that will satisfy a brand promise in a large market. That's where our opportunity is specifically, and that we're leaning into.

Pablo Zuanic: Thank you. One last one, if I may. It is easy to talk in hindsight, right? I am looking at the CAD 3 million to expand capacity at Pacifica 40%. That is about 4.5 million tons. Cascadia was also 4.5 million tons, I think, for CAD 4.5 million. I am just trying to compare the ROI of one versus the other, and whether in hindsight it would have been better just to expand Pacifica more aggressively than having done the Cascadia deal. Thank you.

Margaret Brodie: Hindsight is always 20/20, Pablo. I think as a public company today, we need to demonstrate the path to be a larger company. Cascadia allows us and does have opportunity to go beyond the 4,500 kilograms, which is what we are targeting today, and we have indicated that in the past. We wanted to do both projects. The opportunity to buy a facility very close to us that we could manage, that is close to us and grow, there are very, very few of those. To be able to build that today would be CAD 20 million plus in our view. I think it is time sensitivity. We had always believed that we would do lights at Pacifica. We expected to do that out of cash flow. We have the opportunity to move it forward this year.

Margaret Brodie: As a small team, we cannot do everything at once, and it was economics, highest and best use. Strategically, what the second facility does is de-risks our business from disease risk, pest risk, and things that happen in agriculture, being a single-asset entity. As well, it demonstrates that our team can grow premium quality not only in an organic-certified greenhouse facility that is world-class, and I believe we are one of one doing that, but that we can grow premium indoor quality as well. It gives us confidence to continue to grow the business in a path strategically that I believe adds real value.

Pablo Zuanic: Yeah. Thank you.

Operator: Your next question comes from Nicholas Cortellucci from Atrium Research. Please go ahead.

Nicholas Cortellucci: Hi, team. Thanks for answering my questions here. I wanted a bit more information on the hydrocarbon extraction facility and just the dollars you are saving by doing this and the margin improvement that is expected.

Margaret Brodie: Great. I am going to pass it to Glen on that one.

Glen Ibbott: Yeah, sure. Obviously, with hydrocarbon extraction, the savings will increase materially as we put more volume through there. It actually does a couple things for us. It immediately improves our margins, and if we looked at 2026 volumes, if we put that through the new process, there would be at least CAD 2 million annual savings, likely more. But it really does open the opportunity for us to move more aggressively into other formats or to move aggressively on our vape portfolio and look at expanding that. Again, more volume, more throughput drives the savings up compared to what we would have otherwise had to pay with the external sourcing. So, 2026 volumes, minimum CAD 2 million savings in gross profit a year, but we expect it to go up as we push harder into some of those formats and expand our extraction portfolio offerings.

Nicholas Cortellucci: Got it. Okay, thank you. I was also wondering about Cascadia in terms of a dollar capacity perspective, CAD 2.3 million this quarter. When we get into the back half of next year, what can that kind of look like from a dollar perspective, depending on mix?

Margaret Brodie: That's the problem. I think what I would say when we think about Cascadia today is we're about 1,000 kilos in production off this year that we were expecting, and you can see that being a gap in our results. That's impacting our H2, and we've messaged that very clearly over the last number of months. As we look towards next year, it depends on which market it's going into. Glen Ibbott's sitting here chuckling at me because if it's in the Canadian market, it's not necessarily about the profitability, it's about what form it's taking, i.e., is it a wholesale bulk sale into the international market, or is it going into a branded portfolio? Either way, we are looking to be achieving and targeting margins north of 40% in our products.

Nicholas Cortellucci: Got it. Okay, thank you. The last one for me was just if you could provide some more color on the genetics facility. What was the rationale behind that?

Margaret Brodie: Absolutely. Look, genetics are a key part of cannabis growing, like any agriculture. Very important that we have not only genetics that appeal to consumer, but that grow in a way that we can maximize our yield. What's interesting is we were already working with a genetic house on a contracted basis, but now we're bringing that internal, so there's no real incremental cost, or so it's minor. It's not end-to-end cultivation, but it's a dedicated home for our genetics library. What it means is that we have our genetics stored in a separate location, again, risk management, multi-site opportunity, and we can trial, and it gives us a lot of flexibility. It's really interesting because it avoids a large CapEx that we'd looked at a lot of facilities potentially to be a genetics facility.

Margaret Brodie: This keeps operating costs low, but gives us that flexibility long term to continue to drive and win with genetics.

Nicholas Cortellucci: Very good. Okay, that is all for me. Thank you.

Operator: Your next question comes from Josh Felker with CB1 Capital. Please go ahead.

Josh Felker: Hey, good morning. Thanks for taking my questions. First question, are all yield improvement initiatives from Pacifica also implemented at Cascadia? If not, could they be in the future, or could you give us an idea of when you would evaluate those initiatives for Cascadia?

Margaret Brodie: Can you just clarify that a little bit? Are the ones that we have done? So, it's a different type of facility. So, there is always yield improvements available. Pacifica's had a very good year in terms of what's occurred. We're up 16% year-over-year, and now we're putting the lights in, which we believe will overall increase yield by about 40%. Very, very pleased with that. The Cascadia opportunity, the recent sort of 4 or 5 crop yields are hitting our expectations and what we need that facility to do to turn the economics that we expected. So, very happy with that, but obviously disappointed it took an extra four months from the July timing expectation that we had. There are more opportunities at Cascadia. We will be trialing some of those and we'll be reporting back pending on the results of those.

Margaret Brodie: Some of them are. Light is a very key trigger for plants. As we all know, they like to grow in lights. There's a point of diminishing returns, though, with cannabis. And we are looking at various alternatives, including under-canopy lighting, et cetera, at that facility, though part of that would be increasing the overall yield.

Josh Felker: That helps. Thank you. All right. Now, I have a two-parter on the international market. A few markets are turning online next year. I believe you noted in a recent conference that your team was in France. Could you give us any idea of how many international markets you may be in at the end of maybe 2027? And then, for the second part of that, just could you give us an update on any price compression trends that you're seeing on an international basis? Some peers are noting price compression, albeit at the lower end of the price spectrum. Thank you.

Margaret Brodie: In terms of markets, right now, we are contracted with. We've shipped to three. I expect there could be upwards of 5 to 6 next year. The UK, that would be possible for a Canadian company such as ours to ship to. Switzerland remains a very small market. Brazil, very difficult to get into. So there's a lot of markets that are very small, and we're not going to talk about. What I'd like to address is the larger markets. So we're already in the UK. We're shipping to Germany. We'll be looking at Israel. We're shipping to Australia. France may open up next year, but it would be the very end of the year, and it would be concentrates only. There's still question marks around that. Poland is an open market, and I could see us pursuing that as well. So, all of it is on the table.

Margaret Brodie: In terms of price compression in that market, we have seen price compression, and I believe really driven out of the distributors trying to drive volume. We have seen a trend of increased volumes, but same overall gross profit being delivered on that in some of the markets, and those are the rumors out of them. We have seen that occur in Canada, and things do normalize at a point in time. We are not seeing significant price compression today in our market. In fact, right now, there is a high desire for our product, and we are getting significant inbounds, and we felt pricing actually bounce back the other way towards the positive. That being said, there is always risk with the international markets, and I think you make hay while the sun shines and continue to build a strong domestic business.

Josh Felker: That really helps. And maybe, because I think I am batting cleanup here, could you give us any idea what percentage of sales are from genetics launched in maybe the last 12, 24 months? I will leave it there. Thanks for the questions.

Margaret Brodie: Ooh. I actually am going to have to circle back with you on that. But yes, it is a significant portion of that. Still our number one seller is Comatose, which was Flower of the Year back in 2022 and continues to ride high. But I would have to circle back and send you a note on that, Josh.

Josh Felker: Super. Thank you.

Operator: Thank you. I will now turn the call back to Margaret for closing remarks.

Margaret Brodie: Thank you for joining us today and your continued interest in Rubicon Organics. For those who have been following us, I am excited that what you are going to see with Rubicon in 2027 as we begin to realize the benefits of the work of the last couple of years. As always, I like to leave you with my personal recommendation, and this quarter, it has to be BC Organic Caviar-Z, our first in-house developed genetic and a great example how our cultivation and genetic capabilities come together. Please go out and enjoy some safely.

Operator: Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.

Q3 2026 Rubicon Organics Inc Earnings Call

Demo

Rubicon Organics

Earnings

Q3 2026 Rubicon Organics Inc Earnings Call

ROMJ.V

Monday, November 16th, 2026 at 3:00 PM

Transcript

No Transcript Available

No transcript data is available for this event yet. Transcripts typically become available shortly after an earnings call ends.

Want AI-powered analysis? Try AllMind →

Earnings analysis guides

Methods for extracting KPIs and checking source support when reviewing an earnings call.

Browse all earnings calls